Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors

Next Previous
X
Search
Trial Profile

A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBC 0966 (Primary)
  • Indications Advanced breast cancer; Anaplastic large cell lymphoma; Cancer; Carcinoma; Extranodal NK-T-cell lymphoma; Head and neck cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Peripheral T-cell lymphoma; Squamous cell cancer; T-cell lymphoma; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors SUNHO (China) BioPharmaceutical

    • Most Recent Events

    • 08 Mar 2023 Status changed from not yet recruiting to recruiting.
    • 04 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top